摘要
目的探讨美罗华联合CHOP方案治疗B细胞性非霍奇金淋巴瘤的临床效果及不良反应。方法选择B细胞性非霍奇金淋巴瘤60例随机分成观察组和对照组各30例。观察组采用美罗华联合CHOP方案治疗,对照组仅采用CHOP方案治疗,比较两组临床疗效及不良反应情况。结果观察组患者临床疗效明显优于对照组(P<0.05);不良反应除发热例数多于对照组外(P<0.05),其余两组比较差异无统计学意义(P>0.05)。结论对B细胞性非霍奇金淋巴瘤患者采用美罗华联合CHOP方案治疗,能够有效提高患者的临床疗效,值得临床推广。
Objective To explore the therapeutic effect and adverse reaction of rituximab combined with CHOP regimen in the treatment of B cell non Hodgkin′s lymphoma.Methods Sixty patients with B cell non Hodgkin′s lymphoma were randomly divided into observation group（n=30） and control group（n=30）.The observation group were treated with rituximab combined with CHOP regimen, the patients in control group only received CHOP treatment.The clinical therapeatic effect and adverse reaction between two groups were compared.Results The clinical therapeatic effect in the observation group were significantly higher than that in control group,the difference was statistically significant（P〈0.05）.Conclusion Rituximab combined with CHOP in the treatment of B cells non Hodgkin lymphoma can effectively improve the treatment efficiency,and is worth clinical promotion.
出处
《中国临床新医学》
2014年第10期944-946,共3页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
